When to Stop Using Wegovy: What the Evidence and Official Guidance Say

What the NICE guidance actually says about stopping Wegovy

The most concrete stopping criterion in UK guidance comes from NICE technology appraisal TA875, which recommends semaglutide (Wegovy) only within a specialist weight management service, for a maximum of two years, and with a clear checkpoint: if a patient has not lost at least 5% of their starting body weight after six months at the maintenance dose, continuing treatment should be reconsidered. That six-month checkpoint is not a punishment, it reflects what the STEP 1 trial data showed about who responds to semaglutide and at what pace. People who do respond typically show meaningful progress well within that window.

The two-year maximum in the NICE recommendation is specific to NHS commissioning under TA875. Private prescribing sits outside that framework, but the clinical logic still applies: semaglutide is not a permanent implant, and ongoing treatment needs ongoing justification. Your prescriber should be asking, at every review, whether the benefit-to-risk balance still holds.

Beyond the weight-loss checkpoint, the Wegovy Summary of Product Characteristics (SmPC) on the eMC lists medical reasons to stop: confirmed or suspected pregnancy, active pancreatitis, or a severe hypersensitivity reaction. These are not situations where you taper gradually, they call for immediate contact with your clinical team.

When slowing weight loss does not necessarily mean stopping

There is a misconception worth clearing up quietly: a plateau in weight loss is not, on its own, a reason to stop treatment. Almost everyone experiences a slowdown at some point. The body adapts. What matters is whether that plateau arrives early, before reaching the maintenance dose, or after months of otherwise good progress. Early plateaus at a lower dose often reflect the need for dose titration, not treatment failure. A prescriber looking at your full picture (how long you have been at the current dose, your overall trajectory, any side effects) is in a much better position to interpret a plateau than any rule of thumb.

If you have stopped losing weight and are wondering whether to continue, the practical steps available when weight loss stalls on Wegovy are worth understanding before drawing any conclusions. A dose review, a check on injection technique, and a conversation about lifestyle factors can all shift things before discontinuation is considered.

That said, if you have reached a weight that significantly reduces your health risks and you feel stable, a planned and supervised stop, with a maintenance strategy in place, is a legitimate clinical goal. That is very different from stopping because supply ran out or the cost felt high.

Side effects serious enough to prompt stopping

Most Wegovy side effects are gastrointestinal and tend to settle as the body adjusts. Nausea, loose stools, constipation, and reflux are common, particularly after starting or increasing the dose, and they are rarely a reason to stop altogether. Dose reduction or a slower titration schedule is usually tried first.

Rarer but more serious symptoms are different. The MHRA has highlighted acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe, persistent stomach pain that radiates to the back, with or without vomiting, needs urgent medical attention. If that symptom pattern appears, stop the injection and seek help the same day. Suspected gallbladder problems, significant allergic reactions, or any sudden deterioration in vision if you have diabetes also warrant stopping treatment and contacting a clinician promptly. You can report any suspected side effects through the MHRA's Yellow Card scheme.

Pregnancy is a firm stopping point. The medicine is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. Women using oral contraceptives alongside semaglutide should discuss contraceptive reliability with their prescriber.

Planning what comes after stopping

Weight regain after stopping Wegovy is well documented. The STEP 1 trial extension found that participants who stopped semaglutide after 68 weeks regained a significant portion of the weight lost over the following year, because appetite and hunger signalling returned toward pre-treatment levels. That is biology, not failure.

The implication is that stopping works best when it is planned, not reactive, and our guide on whether and how you can stop using Wegovy is a good starting point for thinking through that decision with your prescriber. A prescriber-supported tapering approach, alongside a realistic maintenance plan covering diet, activity and psychological support, gives the best chance of holding onto the progress made. Some people find it useful to understand the full Wegovy treatment journey in advance so that the exit is built into the plan from the start, rather than treated as an afterthought.

If you are weighing up the cost of continued treatment as part of your thinking, a realistic comparison of Wegovy costs across UK providers can help you understand what you are actually paying for, and whether the clinical support included justifies the price. Stopping because of cost without a maintenance plan tends to produce the worst outcomes.

If any of this raises questions about your current treatment, our prescribers are here. Start your free consultation and a GPhC-registered Independent Prescriber will review your situation the same day.